(UroToday.com) The immunotherapy and beyond thematic session at virtual EAU 2020 featured a series of talks discussing perioperative therapy for urothelial cancer. Dr. Gunter Niegisch discussed the role of chemotherapy remaining the standard of care.
(UroToday.com) The immunotherapy and beyond thematic session at EAU virtual 2020 highlighted several presentations discussing immunotherapy combinations for intermediate-poor risk metastatic renal cell carcinoma (mRCC). Manuela Schmidinger, MD, discussed the aspect of Immuno-Oncology (IO) IO-IO combination therapy for these patients. In the first-line treatment of mRCC for patients with intermediate-poor risk disease, the combination of nivolumab […]
(UroToday.com) The virtual EAU 2020 meeting featured a thematic session discussing immunotherapy combinations for intermediate-poor risk metastatic renal cell carcinoma (mRCC). Axel Merseburger, MD, PhD, discussed the utility of combining Immuno-Oncology (IO) treatment with TKIs. Dr. Merseburger notes that according to older versions of the EAU guidelines, the first-line treatment for IMDC intermediate-poor risk patients is […]
(UroToday.com) Dr. Fred Witjes began his talk explaining that he believes cystoscopy is still needed in the primary diagnosis of bladder tumors. Cystoscopy gives important information regarding multiplicity, size, stage, the grade of bladder tumors, and OR planning.
Alicia Morgans: Hi, this is Alicia Morgans, GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to talk today with a friend and colleague, Dr. Brad McGregor, who is the Clinical Director of the Lank Center for GU Oncology at the Dana-Farber Cancer Institute and someone who’s been really pushing […]
(UroToday.com) Dr. Peter Black gave a nice overview of the current and future treatment options for non- muscle-invasive bladder cancer (NMIBC) patients.
(UroToday.com) At the European Association of Urology (EAU) Virtual 2020 meeting’s Immunotherapy and Beyond Thematic session, Dr. Joost Boormans discussed PD-1/PD-L1 inhibitors replacing perioperative chemotherapy for urothelial cancer.
(UroToday.com) At the Society of Urologic Oncology (SUO) – American Urologic Association (AUA) 2020 Virtual Summer Webcast Program’s renal cancer session, Professor Alexander Kutikov discussed active surveillance for small renal masses and expanding indications for surveillance. Dr. Kutikov notes that there are treatment disconnect concerns in that there is an increasing incidence of renal mass […]
(UroToday.com) As part of a plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting assessing “modern prostate cancer imaging in daily practice”, Alastair Lamb Ph.D, FRCS(Urol), examined the question of what to do in men at risk of prostate cancer for whom you have decided not to biopsy or who have had an […]
(UroToday.com) As part of the “Game-changing Session 2” plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Grimm presented an analysis of the recurrence risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for European Organization for Research and Treatment of Cancer […]
